Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep 17;4:19-26.
doi: 10.2147/POR.S51838. eCollection 2013.

Autoinjectors for Administration of Interferon beta-1b in Multiple Sclerosis: Patient Preferences and the ExtaviPro™ 30G and Betacomfort ® Devices

Affiliations
Free PMC article

Autoinjectors for Administration of Interferon beta-1b in Multiple Sclerosis: Patient Preferences and the ExtaviPro™ 30G and Betacomfort ® Devices

Kunal Thakur et al. Pragmat Obs Res. .
Free PMC article

Abstract

Background: The ExtaviPro™ 30G autoinjector has been developed for self-administration of interferon beta-1b (Extavia®), which is used as a first-line, parenteral, disease-modifying therapy in multiple sclerosis (MS). The aim of this survey was to investigate patients' perceptions of the importance of different general attributes of autoinjectors, and patient preferences when comparing the ExtaviPro™ 30G and Betacomfort® autoinjectors.

Method: The survey was conducted in France, Germany, Italy, and the USA in patients with relapsing-remitting MS who had been using an autoinjector for at least 1 year. Participants examined the ExtaviPro™ 30G and Betacomfort® devices, viewed fact sheets, and watched a video of these autoinjectors in use, then scored nine prespecified attributes of autoinjectors in terms of importance on a scale of 1-7 (1 = not at all important; 7 = extremely important). They then indicated which device they preferred, both overall and by individual attribute.

Results: Among the 201 participants who completed the survey, being reliable to use was considered the most important general attribute of autoinjectors, followed by attributes associated with convenience (ease of operation, one-handed injection, ease of reach of injection sites, ergonomic shape). For each of the nine attributes, a significantly higher proportion of participants (74%-94% by attribute; P < 0.05 for each) preferred ExtaviPro™ 30G to the Betacomfort® autoinjector, and 173 (86%) participants indicated that they preferred ExtaviPro™ 30G overall (P < 0.05).

Conclusion: The results of this survey suggest that patients with MS rate reliability and convenience as the most important general attributes of autoinjectors, and are more likely to prefer ExtaviPro™ 30G to the Betacomfort® autoinjector for routine self-administration of interferon beta-1b.

Keywords: autoinjector; interferon beta; multiple sclerosis; patient preference; relapsing-remitting; self-administration; subcutaneous injectors.

Figures

Figure 1
Figure 1
Layout of devices, fact sheets, and video reviewed by participants. The positions of the autoinjectors and their fact sheets were alternated between interviews. ExtaviPro™ 30G (Novartis Pharma AG, Basel, Switzerland) is on the left in this image.
Figure 2
Figure 2
Patient flow. Abbreviation: RRMS, relapsing-remitting multiple sclerosis.
Figure 3
Figure 3
Mean scores overall and by country for prespecified general attributes of autoinjectors. Data are presented as mean scores of importance, both overall and by country. Notes: aP < 0.05, overall score compared to other attributes; bP < 0.05, overall scores compared to lowest-ranking attributes.
Figure 4
Figure 4
Proportion of participants expressing an autoinjector preference, both overall and by attribute. Notes: P < 0.05 for the difference between autoinjectors, both overall and by attribute. *Novartis Pharma AG, Basel, Switzerland; **Bayer Schering Pharma AG, Berlin, Germany.
Figure 5
Figure 5
Number of participants citing each prespecified attribute as the main reason for their overall preference of autoinjector. Notes: *Novartis Pharma AG, Basel, Switzerland; **Bayer Schering Pharma AG, Berlin, Germany.

Similar articles

See all similar articles

Cited by 5 articles

References

    1. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):655–661. - PubMed
    1. European Study Group on interferon beta-1b in secondary progressive MS Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet. 1998;352(9139):1491–1497. - PubMed
    1. Durelli L, Verdun E, Barbero P, et al. Independent Comparison of Interferon (INCOMIN) Trial Study Group Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) Lancet. 2002;359(9316):1453–1460. - PubMed
    1. Panitch H, Miller A, Paty D, Weinshenker B, North American Study Group on Interferon beta-1b in Secondary Progressive MS Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004;63(10):1788–1795. - PubMed
    1. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67(7):1242–1249. - PubMed

LinkOut - more resources

Feedback